This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ralph W. Kuncl, MD, PhD
Department of Neurology Johns Hopkins University School of Medicine Baltimore, MD 21205

Greg Duncan, MD
Department of Orthopedic Surgery UCLA Center for Health Sciences Los Angeles, CA 90024

Arch Neurol. 1988;45(3):245-246.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—The first case of human colchicine myopathy was reported by Kontos¹ in 1962. The case was somewhat misleading since the disorder occurred at an unusually high "nonpharmacologic" dose of colchicine; the syndrome was unsubstantiated histopathologically since muscle biopsy results were said to be normal. Later, the morphology of a colchicine-induced myopathy in laboratory animals was well described.² The recent case of colchicine neuro-muscular disease reported by Riggs et al³ was valuable in being the first report to document the human intoxication histopathologically. The authors described central architectural and vacuolar changes of skeletal muscle fibers, and showed the coexistent axonal degeneration. However, this second case was also unusual. First, the disorder was the result of multiple acute intoxications because of a bizarre self-dosing schedule. Second, the electromyogram showed only signs of axonal neuropathy and denervation. Third, the serum creatine kinase level remained mildly elevated . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?